URGENT: Risk of heart complications is higher after COVID-19 injections (Deanna, Canadian COVID Care Alliance (CCCA)); BOTTOM LINE IS THAT THE CDC HAS LIED, MALFEASANT

by Paul Alexander

Buchan et al.: "Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada"

SOURCE:

https://www.bitchute.com/video/JBmMFfpC28ok/?utm_source=substack&utm_medium=email

“The rate of myocarditis or pericarditis tended to be higher after the second dose of the mRNA vaccine than after the first dose, particularly for individuals who received mRNA-1273 as the second dose of the series (Table 2).

The highest rate of myocarditis or pericarditis was observed among male individuals aged 18 to 24 years following mRNA-1273 as the second dose (299.5 cases per 1 000 000 doses [95% CI, 171.2-486.4 cases per 1 000 000 doses]) compared with BNT162b2 as the second dose (59.2 cases per 1 000 000 doses [95% CI, 19.2-138.1 cases per 1 000 000 doses]) in this age group.

The second highest rate was observed among male individuals aged 12 to 17 years following their second dose of BNT162b2 (97.3 cases per 1 000 000 doses [95% CI, 60.3-148.8 cases per 1 000 000 doses]).”

SOURCE:

https://pubmed.ncbi.nlm.nih.gov/35749115/

“The findings of this population-based cohort study of Ontario adolescents and adults with myocarditis or pericarditis following mRNA COVID-19 vaccination suggest that vaccine products and interdose intervals, in addition to age and sex, may be associated with the risk of myocarditis or pericarditis after receipt of these vaccines.”

Among all ages and sexes combined, rates of myocarditis or pericarditis were significantly higher for individuals with shorter interdose intervals for either vaccine received as the second dose (for intervals ≤30 days: BNT162b2, 52.1 cases per 1 000 000 doses [95% CI, 31.8-80.5 cases per 1 000 000 doses]; mRNA-1273, 83.9 cases per 1 000 000 doses [95% CI, 47.0-138.4 cases per 1 000 000 doses]; for intervals ≥56 days: BNT162b2, 9.6 cases per 1 000 000 doses [95% CI, 6.5-13.6 cases per 1 000 000 doses]; mRNA-1273, 16.2 cases per 1 000 000 doses [95% CI, 10.2-24.6 cases per 1 000 000 doses]) (Figure, A).

This trend was also observed among male individuals aged 18 to 24 years across vaccine product combinations (eTable 5 in the Supplement). Overall, 95% CIs overlapped when comparing homologous with heterologous schedules within second-dose products.’

‘Among individuals who received their second dose on or after June 1, 2021, adjusted rate ratios (aRRs) for myocarditis or pericarditis comparing mRNA-1273 with BNT162b2 were significantly higher among male individuals aged 18 to 24 years (aRR, 6.6; 95% CI, 3.3-13.2) and 25 to 39 years (aRR, 5.1; 95% CI, 2.3-11.5) and among female individuals aged 18 to 24 years (aRR, 9.6; 95% CI, 1.9-48.8) (Table 3).

However, the 95% CIs in this analysis were wide owing to small numbers (ie, ≤10 events after a second mRNA dose among female individuals aged 18 to 24 years).’

‘Consistent with other surveillance systems and studies,13,14 we found that rates of myocarditis or pericarditis were highest among young male individuals following a second dose and that events were tightly clustered within the first week after vaccination. Rates were higher following a second dose of either mRNA-1273 or BNT162b2 compared with a first dose, and the rates following a second dose of mRNA-1273 were higher than those following a second dose of BNT162b2, in particular for young male individuals.’

see stack by my brother Dr. Bridle on same topic teeing this up:

COVID Chronicles
Risk of Heart Complications is Higher After COVID-19 Injections
I am a proud member of the Canadian COVID Care Alliance (CCCA), which is a group of hundreds of scientists, physicians, and other health care professionals from across Canada, with even more members of the public. It is a safe place where the science and politics underpinning COVID-19 can be discussed, questioned and debated in a respectful, well-organi…
Read more